List of Figures
Figure 1: Risk Evaluation and Mitigation Strategies, Opioids, 2011
Figure 2: Risk Evaluation and Mitigation Strategies, Requirement of additional REMS component, 2008-2010
Figure 3: Risk Evaluation and Mitigation Strategies, Erythropoiesis-Stimulating Agents, 2011
Figure 4: Risk Evaluation and Mitigation Strategies, Stages of Drug Development, 2011
Figure 5: Risk Evaluation and Mitigation Strategies, Post Marketing Surveillance System , 2011
Figure 6: Risk Evaluation and Mitigation Strategies, System of safety data gathering, 2011
Figure 7: Risk Evaluation and Mitigation Strategies, Number of Adverse Events in the US, 2000-2011
Figure 8: Risk Evaluation and Mitigation Strategies, Healthcare Expenditure 1998-2008
Figure 9: Risk Evaluation and Mitigation Strategies, Components of REMS
Figure 10: Risk Evaluation and Mitigation Strategies, REMS Approvals (2008-2010)
Figure 11: Risk Evaluation and Mitigation Strategies, Components of REMS, 2008-2010
Figure 12: Risk Evaluation and Mitigation Strategies, Requirement of additional REMS component, 2008-2010
Figure 13: Risk Evaluation and Mitigation Strategies, Safety Issues, 2008-2010
Figure 14: Risk Evaluation and Mitigation Strategies, Components of REMS, 2008
Figure 15: Risk Evaluation and Mitigation Strategies, Components of REMS, 2009
Figure 16: Risk Evaluation and Mitigation Strategies, Components of REMS, 2010
Figure 17: Risk Evaluation and Mitigation Strategies, Implications for Stakeholders
Figure 18: Risk Evaluation and Mitigation Strategies, Important Drug Classes Requiring REMS
Figure 19: Risk Evaluation and Mitigation Strategies, Number of ED Visits Due To Drug Abuse in the US, 2004 and 2008
Figure 20: Risk Evaluation and Mitigation Strategies, Number of Opioid drug prescriptions (in million), 1991-2009
Figure 21: Risk Evaluation and Mitigation Strategies, Number of Emergency Department Visits in the US, 2004-2008
Figure 22: Risk Evaluation and Mitigation Strategies, Opioids, 2011
Figure 23: Risk Evaluation and Mitigation Strategies, Onsolis, 2011
Figure 24: Risk Evaluation and Mitigation Strategies, Erythropoiesis-Stimulating Agents, 2011
Figure 25: Risk Evaluation and Mitigation Strategies, Accutane Case Study, 2011
Figure 26: Risk Evaluation and Mitigation Strategies, Tysabri Case Study, 2011
Figure 27: Risk Evaluation and Mitigation Strategies, Nplate, Case Study, 2011
Figure 28: Risk Evaluation and Mitigation Strategies, Electronic Data Capture through e-CRF, 2009
Figure 29: Risk Evaluation and Mitigation Strategies, EDC System- Cost Saving Scenario, 2009
Figure 30: Risk Evaluation and Mitigation Strategies, EDC Cost Saving in Clinical Trials – By Therapy, 2009
Figure 31: Risk Evaluation and Mitigation Strategies, Cost Saving Scenario of ePRO Solutions, 2009
Figure 32: Risk Evaluation and Mitigation Strategies, Case Study of ePRO Solutions, 2009
Figure 33: Risk Evaluation and Mitigation Strategies, Integration of IVR with other Systems, 2009
Figure 34: Risk Evaluation and Mitigation Strategies, Clinical Data Management Flow, 2009
Figure 35: Risk Evaluation and Mitigation Strategies, Paper Based Pedigree in a Pharmaceutical Supply Chain
Figure 36: Risk Evaluation and Mitigation Strategies, Inflexxion, Snapshot, 2011
Figure 37: Risk Evaluation and Mitigation Strategies, inVentiv health, Snapshot, 2011
Figure 38: Risk Evaluation and Mitigation Strategies, BioTrak Research, Snapshot, 2011
Figure 39: Risk Evaluation and Mitigation Strategies, BioTrak Research, Case Study, 2011